Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 58, Issue 6, 2003, Pages 481-485

  Horak, Friedrich ^a,c   Stubner P ^a   Zieglmeyer, R ^a   Harris, A G ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antihistamine; Desloratadine; Nasal congestion; Rhinomanometry; Seasonal allergic rhinitis

Indexed keywords

DESLORATADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; PLACEBO;

ADULT; ALLERGIC RHINITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; ENVIRONMENTAL EXPOSURE; FEMALE; GRASS POLLEN; HEADACHE; HUMAN; MALE; NAUSEA; NOSE AIRFLOW; NOSE CONGESTION; NOSE SECRETION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEASONAL VARIATION; SOMNOLENCE; SYMPTOMATOLOGY; TREATMENT OUTCOME; XEROSTOMIA;

ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENVIRONMENTAL EXPOSURE; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LORATADINE; MALE; NASAL CAVITY; NASAL MUCOSA; PLACEBOS; POACEAE; POLLEN; PULMONARY VENTILATION; RHINITIS, ALLERGIC, SEASONAL;

EID: 0038693805     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1398-9995.2003.00148.x     Document Type: Article

References (26)

1. KAY AB. Allergy and allergic diseases (Part 1 of 2). N Engl J Med 2001;344:30-37.
2. HEAVEY DJ, LUMLEY P, BARROW SE, MURPHY MB, HUMPHREY PP, DOLLERY CT. Effects of intravenous infusions of prostaglandin D2 in man. Prostaglandins 1984;28:755-767.
3. MIADONNA A, TEDESCHI A, LEGGIERI E, LORINI M, FOLCO G, SALA A, QUALIZZA R, FROLDI M, ZANUSSI C. Effects of nasal challenge with histamine, leukotriene C4 and prostaglandin D2 in patients with grass-pollen allergic rhinitis. Folia Allergol Immunol Clin 1986;33:279-284.
4. WANG D, CLEMENT P, SMITZ J. Effect of H1 and H2 antagonists on nasal symptoms and mediator release in atopic patients after nasal allergen challenge during the pollen season. Acta Otolaryngol 1996;116:91-96.
5. SANICO AM, ATSUTA S, PROUD D, TOGIAS A. Dose-dependent effects of capsaicin nasal challenge: in vivo evidence of human airway neurogenic inflammation. J Allergy Clin Immunol 1997;100:632-641.
6. EMERY BE, WHITE MV, IGARASHI Y, MULLOL J, BERKEBILE C, PEDEN D, LOTZE MT, KALINER MA. The effect of IL-4 on human nasal mucosal responses. J Allergy Clin Immunol 1992;90:772-781.
7. WEINER JM, ABRAMSON MJ, PUY RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. Br Med J 1998;317:1624-1629.
8. MYGIND N, NIELSEN LP, HOFFMANN HJ, SHUKLA A, BLUMBERGA G, DAHL R, JACOBI H. Mode of action of intranasal corticosteroids. J Allergy Clin Immunol 2001;108 (Suppl. 1):S16-S25.
9. SPECTOR S. Ideal pharmacotherapy for allergic rhinitis. J Allergy Clin Immunol 1999;103 (Suppl.):386-387.
10. GENTILE DA, FRIDAY GA, SKONER DP. Management of allergic rhinitis: antihistamines and decongestants. Immunol Allergy Clin North Am 2000;20:355-368.
11. FIREMAN P. Treatment strategies designed to minimize medical complications of allergic rhinitis. Am J Rhinol 1997;11:95-102.
12. KREUTNER W, HEY JA, ANTHES J, BARNETT A, YOUNG S, TOZZI S. Pre-clinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergic effects. Arzneimittelforschung 2000;50:345-352.
13. 1-receptor antagonist, in patients with seasonal allergic rhinitis. Clin Drug Invest 2001;21:25-32.
14. DUBUSKE LM and the Desloratadine Study Group. Once-daily desloratadine reduces the symptoms of perennial allergic rhinitis for at least 4 weeks. J Allergy Clin Immunol 2001;107:S159.
15. RING J, HEIN R, GAUGER A. Desloratadine in the treatment of chronic idiopathic urticaria. Allergy 2001;56:28-32.
16. NAYAK AS, SCHENKEL E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 2001;56:1077-1080.
17. HORAK F, STUBNER UP, ZIEGLMAYER R, HARRIS AG. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol 2002;109 (6 Pt 1):956-961.
18. DAY JH, BRISCOE M, RAFEIRO E, CHAPMAN P, KRAMER B. Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system. Ann Allergy Asthma Immunol 2001;87:474-481.
19. 1-receptor antagonist, in the treatment of fall allergies. Asthma Allergy Proc 1998;19:135-141.
20. RATNER PH, LIM JC, GEORGES GC. Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2000;105:1101-1107.
21. LEYNADIER F, MEES K, ARENDT C, PINELLI ME. Efficacy and safety of levocetirizine in seasonal allergic rhinitis. Acta Oto-rhino-laryngol Belg 2001;55:305-312.
22. BROIDE DH. Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol 2001;108 (Suppl. 2):S65-S71.
23. GEHA RS, MELTZER EO. Desloratadine: a new, nonsedating, oral antihistamine. J Allergy Clin Immunol 2001;107:751-762.
24. KLEINE-TEBBE J, JOSTIES C, FRANK G, STALLEICKEN D, FRIESE A, SCHUNACK W, KUNKEL G, CZARNETZKI BM. Inhibition of IgE-mediated and IgE-independent histamine release from human basophil leukocytes in vitro by H1-antagonist, descarbo-ethoxy-loratadine. J Allergy Clin Immunol 1994;93:494-500.
25. GENOVESE A, PATELLA V, DE CRESCENZO G, DE PAULIS A, SPADARO G, MARONE G. Loratadine and desethoxylcarbonylloratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells. Clin Exp Allergy 1997;27:559-567.
26. SCHROEDER JT, SCHLEIMER RP, LICHTENSTEIN LM, KREUTNER W. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy 2001;31:1-10.